-
公开(公告)号:WO0220533A3
公开(公告)日:2002-08-22
申请号:PCT/US0126878
申请日:2001-08-29
Applicant: ABBOTT LAB
Inventor: BASHA FATIMA Z , WENDT MICHAEL D , PRATT JOHN K
IPC: A61P13/00 , C07D519/00 , A61K31/5365
CPC classification number: C07D519/00
Abstract: The present invention relates to compounds having formula I and to pharmaceutically acceptable salts thereof. Compounds of formula I inhibit a1 adrenoreceptors and may be useful for treating benign prostatic hyperplasia (also called benign prostatic hypertrophy) and other urological diseases such as bladder outlet obstruction, neurogenic bladder and gynecological syndromes.
Abstract translation: 本发明涉及具有式I的化合物及其药学上可接受的盐。 式I的化合物抑制a1肾上腺素受体,并且可用于治疗良性前列腺增生(也称为良性前列腺肥大)和其它泌尿系统疾病,例如膀胱出口阻塞,神经源性膀胱和妇科综合征。
-
公开(公告)号:WO2007008627A2
公开(公告)日:2007-01-18
申请号:PCT/US2006026424
申请日:2006-07-07
Applicant: ABBOTT LAB , WENDT MICHAEL D , SHEN WANG , DICKMAN DANIEL A , DING HONG , THOMAS SHEELA A , AUGERI DAVID , ELMORE STEVEN W
Inventor: WENDT MICHAEL D , SHEN WANG , DICKMAN DANIEL A , DING HONG , THOMAS SHEELA A , AUGERI DAVID , ELMORE STEVEN W
IPC: A61K31/192 , A61P35/00 , C07C15/12
CPC classification number: C07C311/41 , C07C63/48 , C07C63/49 , C07C65/26 , C07C65/28 , C07C205/58 , C07C229/52 , C07C229/56 , C07C233/81 , C07C311/13 , C07C311/18 , C07C311/21 , C07C311/37 , C07C311/44 , C07C323/20 , C07C323/25 , C07C323/62 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/10 , C07C2603/18 , C07C2603/74 , C07D207/30 , C07D213/53 , C07D215/12 , C07D215/48 , C07D333/34
Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.
Abstract translation: 公开了抑制抗细胞凋亡Mcl-1蛋白活性的化合物,含有该化合物的组合物和治疗疾病的方法,其表达为Mcl-1蛋白。
-
3.APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 审中-公开
Title translation: 用于治疗癌症和免疫和自发性疾病的病毒诱导剂公开(公告)号:WO2010083441A3
公开(公告)日:2010-09-10
申请号:PCT/US2010021243
申请日:2010-01-15
Applicant: ABBOTT LAB , HEXAMER LAURA , DING HONG , ELMORE STEVEN W , KUNZER AARON R , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WENDT MICHAEL D
Inventor: HEXAMER LAURA , DING HONG , ELMORE STEVEN W , KUNZER AARON R , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WENDT MICHAEL D
IPC: C07D209/08 , A61K31/635 , A61P35/00 , C07D213/71 , C07D231/56 , C07D235/04 , C07D265/02 , C07D285/14 , C07D295/155 , C07D311/14
CPC classification number: C07D295/155 , C07D209/08 , C07D213/71 , C07D231/56 , C07D235/04 , C07D265/02 , C07D285/14 , C07D311/14
Abstract: Disclosed are compounds of formula (I) which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡Bcl-2蛋白活性的式(I)化合物,含有该化合物的组合物和治疗其中表达抗凋亡Bcl-2蛋白的疾病的方法。
-
4.
公开(公告)号:WO2010065824A3
公开(公告)日:2010-10-07
申请号:PCT/US2009066722
申请日:2009-12-04
Applicant: ABBOTT LAB , BRUNCKO MILAN , DAI YUJIA , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D
Inventor: BRUNCKO MILAN , DAI YUJIA , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D
IPC: A61P35/00 , A61K31/496 , C07D403/12
CPC classification number: C07D405/12 , C07D209/08 , C07D211/58 , C07D213/74 , C07D213/84 , C07D231/56 , C07D235/06 , C07D277/24 , C07D295/30 , C07D309/04 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
-
5.SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 审中-公开
Title translation: 作为治疗癌症和免疫疾病的BCL-2-选择性病毒诱导剂的磺酰胺衍生物公开(公告)号:WO2010065865A3
公开(公告)日:2010-09-16
申请号:PCT/US2009066790
申请日:2009-12-04
Applicant: ABBOTT LAB , BRUNCKO MILAN , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D
Inventor: BRUNCKO MILAN , DING HONG , DOHERTY GEORGE A , ELMORE STEVEN W , HASVOLD LISA , HEXAMER LAURA , KUNZER AARON R , MANTEI ROBERT A , MCCLELLAN WILLIAM J , PARK CHANG H , PARK CHEOL-MIN , PETROS ANDREW M , SONG XIAOHONG , SOUERS ANDREW J , SULLIVAN GERARD M , TAO ZHI-FU , WANG GARY T , WANG LE , WANG XILU , WENDT MICHAEL D
IPC: C07D405/12 , A61K31/404 , A61P35/00 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12
CPC classification number: C07D405/12 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D417/12
Abstract: Disclosed are compounds of formula (I) which inhibit the activity of anti-apoptotic BcI -2 or BcI -xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti -aooptotic Bcl-2 protein.
Abstract translation: 公开了抑制抗凋亡BcI -2或BcI-xL蛋白活性的式(I)化合物,含有该化合物的组合物和治疗其中表达抗细胞凋亡Bcl-2蛋白的疾病的方法。
-
公开(公告)号:WO2008131000A3
公开(公告)日:2008-12-18
申请号:PCT/US2008060472
申请日:2008-04-16
Applicant: ABBOTT LAB , ELMORE STEVEN W , SOUERS ANDREW J , BRUNCKO MILAN , SONG XIAOHONG , WANG XILU , HASVOLD LISA A , WANG LE , KUNZER AARON R , PARK CHEOL-MIN , WENDT MICHAEL D , TAO ZHI-FU
Inventor: ELMORE STEVEN W , SOUERS ANDREW J , BRUNCKO MILAN , SONG XIAOHONG , WANG XILU , HASVOLD LISA A , WANG LE , KUNZER AARON R , PARK CHEOL-MIN , WENDT MICHAEL D , TAO ZHI-FU
IPC: C07D209/34 , A61K31/404 , A61P35/00 , C07D401/12 , C07D413/06 , C07D417/04
CPC classification number: C07D209/42 , A61K31/5377 , C07D209/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D491/113
Abstract: Compounds of formula (I) which inhibit the activity of anti-apoptotic McI-I protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated McI-I protein are disclosed.
Abstract translation: 公开了抑制抗凋亡McI-1蛋白活性的式(I)化合物,含有该化合物的组合物,以及治疗涉及过表达或未调节的McI-1蛋白的疾病的方法。
-
公开(公告)号:WO2005049593A3
公开(公告)日:2005-07-07
申请号:PCT/US2004036770
申请日:2004-11-03
Applicant: ABBOTT LAB , BRUNCKO MILAN , ELMORE STEVEN , KUNZER AARON R , LYNCH CHRISTOPHER L , WANG XILU , WENDT MICHAEL D
Inventor: BRUNCKO MILAN , ELMORE STEVEN , KUNZER AARON R , LYNCH CHRISTOPHER L , WANG XILU , WENDT MICHAEL D
IPC: A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/635 , C07C311/51 , C07C323/25 , C07D205/04 , C07D207/16 , C07D211/44 , C07D211/46 , C07D211/60 , C07D211/74 , C07D213/70 , C07D213/75 , C07D233/06 , C07D233/84 , C07D239/06 , C07D263/58 , C07D277/36 , C07D277/74 , C07D295/13 , C07D295/155 , C07D295/192 , C07D307/64 , C07D335/02 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/02 , C07D413/12 , C07D417/02 , C07D487/04 , C07D487/08 , C07D295/14 , A61P35/00
CPC classification number: C07D277/74 , C04B35/632 , C07C323/25 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D211/46 , C07D211/60 , C07D211/74 , C07D213/70 , C07D213/75 , C07D233/06 , C07D233/84 , C07D239/06 , C07D263/58 , C07D277/36 , C07D295/13 , C07D295/192 , C07D307/64 , C07D335/02 , C07D401/12 , C07D403/04 , C07D409/12 , C07D487/04 , C07D487/08
Abstract: Disclosed are N-acylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which are expressed one or more than one of an anti-apoptotic protein family member.
Abstract translation: 公开了抑制抗凋亡蛋白家族成员的活性的N-酰基磺酰胺化合物,含有化合物的组合物和该化合物用于制备用于治疗疾病的药物的用途,其中表达一种或多种抗凋亡蛋白家族成员 。
-
公开(公告)号:WO0224636A3
公开(公告)日:2002-09-26
申请号:PCT/US0129432
申请日:2001-09-20
Applicant: ABBOTT LAB
Inventor: MCCLELLAN WILLIAM , OOST THORSTEN , BRUNCKO MILAN , WANG XILU , AUGERI DAVID J , BAUMEISTER STEVEN A , DICKMAN DANIEL A , DING HONG , DINGES JURGEN , FESIK STEPHEN W , HAJDUK PHILIP J , KUNZER AARON R , NETTESHEIM DAVID G , PETROS ANDREW M , ROSENBERG SAUL H , SHEN WANG , THOMAS SHEELA A , WENDT MICHAEL D
IPC: A61K31/18 , A61K31/428 , A61K31/63 , A61K31/635 , A61P9/10 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , C07C311/46 , C07C311/51 , C07C317/28 , C07C323/12 , C07C323/17 , C07C323/25 , C07C323/30 , C07C323/37 , C07C323/43 , C07C323/44 , C07C323/48 , C07C323/58 , C07C323/60 , C07D203/10 , C07D205/04 , C07D205/12 , C07D207/09 , C07D207/24 , C07D207/40 , C07D207/404 , C07D209/08 , C07D209/52 , C07D209/54 , C07D209/96 , C07D211/14 , C07D211/44 , C07D211/70 , C07D211/74 , C07D213/56 , C07D213/61 , C07D213/64 , C07D213/69 , C07D213/70 , C07D213/71 , C07D215/14 , C07D215/22 , C07D215/227 , C07D215/38 , C07D215/48 , C07D217/04 , C07D221/20 , C07D231/12 , C07D233/60 , C07D235/08 , C07D235/26 , C07D241/08 , C07D241/16 , C07D249/04 , C07D263/32 , C07D263/56 , C07D263/58 , C07D277/62 , C07D277/64 , C07D295/13 , C07D295/155 , C07D295/16 , C07D295/185 , C07D295/20 , C07D295/205 , C07D295/215 , C07D295/26 , C07D307/14 , C07D317/54 , C07D333/28 , C07D333/68 , C07D333/70 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/06 , C07D417/12 , C07D451/02 , C07D491/107 , C07D295/14 , C07D317/58
CPC classification number: C07D207/404 , C07C311/51 , C07C317/28 , C07C323/12 , C07C323/17 , C07C323/25 , C07C323/30 , C07C323/37 , C07C323/58 , C07C323/60 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2602/28 , C07C2602/42 , C07C2602/44 , C07C2603/74 , C07D203/10 , C07D205/12 , C07D207/24 , C07D209/08 , C07D209/96 , C07D211/44 , C07D211/70 , C07D211/74 , C07D213/61 , C07D213/70 , C07D213/71 , C07D215/14 , C07D215/227 , C07D215/48 , C07D217/04 , C07D221/20 , C07D231/12 , C07D235/08 , C07D235/26 , C07D241/16 , C07D249/04 , C07D263/56 , C07D263/58 , C07D277/62 , C07D277/64 , C07D295/13 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D307/14 , C07D317/54 , C07D333/28 , C07D333/68 , C07D401/06 , C07D401/12 , C07D405/04 , C07D417/12 , C07D451/02
Abstract: N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
Abstract translation: 具有式(I)的N-苯甲酰基芳基磺酰胺是BCL-X1抑制剂,可用于促进细胞凋亡。 还公开了BCL-X1抑制组合物和促进哺乳动物细胞凋亡的方法。
-
公开(公告)号:WO9905096A3
公开(公告)日:1999-06-03
申请号:PCT/US9815386
申请日:1998-07-24
Applicant: ABBOTT LAB
Inventor: GEYER ANDREW G , MCCLELLAN WILLIAM J , ROCKWAY TODD W , STEWART KENT D , WEITZBERG MOSHE , WENDT MICHAEL D
IPC: C07D295/08 , A61K31/155 , A61K31/341 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/42 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/47 , A61K31/472 , A61K31/505 , A61K31/5375 , A61P15/00 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07C257/18 , C07C259/18 , C07C271/22 , C07C271/30 , C07C271/66 , C07C275/40 , C07C275/42 , C07C275/64 , C07C311/13 , C07C311/15 , C07C311/16 , C07C311/47 , C07C323/56 , C07C323/62 , C07D207/08 , C07D207/337 , C07D209/08 , C07D213/56 , C07D213/58 , C07D213/74 , C07D213/75 , C07D215/38 , C07D217/02 , C07D231/12 , C07D231/40 , C07D231/56 , C07D237/20 , C07D239/28 , C07D239/34 , C07D239/42 , C07D239/54 , C07D239/545 , C07D241/18 , C07D241/20 , C07D261/08 , C07D261/14 , C07D263/32 , C07D277/20 , C07D277/30 , C07D277/34 , C07D277/42 , C07D277/44 , C07D295/092 , C07D303/46 , C07D307/16 , C07D307/18 , C07D307/54 , C07D307/64 , C07D317/58 , C07D317/66 , C07D317/68 , C07D333/24 , C07D405/12 , C07D521/00 , C07D217/04 , C07D233/54 , C07D295/14 , C07D307/32 , C07D307/80
CPC classification number: C07D249/08 , C07C257/18 , C07C259/18 , C07C271/22 , C07C271/30 , C07C271/66 , C07C275/40 , C07C311/13 , C07C311/16 , C07C323/56 , C07C323/62 , C07C2601/02 , C07C2601/04 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07D207/08 , C07D209/08 , C07D213/58 , C07D213/74 , C07D215/38 , C07D217/02 , C07D231/12 , C07D231/40 , C07D231/56 , C07D233/56 , C07D237/20 , C07D239/34 , C07D239/42 , C07D239/545 , C07D241/18 , C07D241/20 , C07D261/14 , C07D263/32 , C07D277/34 , C07D277/42 , C07D295/088 , C07D303/46 , C07D307/16 , C07D307/18 , C07D307/54 , C07D307/64 , C07D317/68 , C07D333/24 , C07D405/12
Abstract: Compounds having formula (I) are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.
Abstract translation: 具有式(I)的化合物是尿激酶的抑制剂,可用于治疗尿激酶起作用的疾病。 还公开了尿激酶抑制组合物和抑制哺乳动物尿激酶的方法。
-
公开(公告)号:DOP2012000153A
公开(公告)日:2017-04-30
申请号:DO2012000153
申请日:2012-06-01
Applicant: ABBOTT LAB
Inventor: ELMORE STEVEN W , SOUERS ANDREW J , BRUNCKO MILAN , SONG XIAOHONG , WANG XILU , WANG LE , PARK CHEOL-MIN , TAO ZHI-FU , DING HONG , HASVOLD LISA , HEXAMER LAURA , MCCLELLAN WILLIAM J , PARK CHANG H , PETROS ANDREW M , SULLIVAN GERARD M , WANG GARY T , WENDT MICHAEL D , MANTEI ROBERT A , HANSEN TODD M , DOHERTY GEORGE A , KUNZER AARON
IPC: A61K31/404 , A61P35/00 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D235/26 , C07D249/04
Abstract: Compuestos de Fórmula I derivados de sulfonamida, por ejemplo, N-({5-cloro-6-[(4,4-difluorociclohexil)metoxi]piridin-3-il}sulfonil)-4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-2-(1H-indazol-4-iloxi)benzamida, que inhiben la actividad de las proteínas anti-apoptóticas Bcl- 2 o Bcl-XL y composiciones que contienen dichos compuestos, los cuales sirven para preparer un medicamento útil en el tratamiento de enfermedades durante las cuales se expresa la proteína anti-apoptótica Bcl-2, por ejemplo, cáncer de vejiga, cáncer de cerebro, cáncer de mamas, cáncer de médula ósea, cáncer cervical, leucemia linfocítica crónica, cáncer colorrectal, cancer de esófago, cáncer hepatocelular, leucemia linfoblástica, linfoma folicular, una malignidad linfoide originada en células T o células B, melanoma, leucemia mielógena, mieloma, cáncer oral, cáncer de ovarios, cáncer de pulmón de células no pequeñas, cáncer de próstata, cáncer de pulmón de células pequeñas o cáncer de bazo, entre otras.
-
-
-
-
-
-
-
-
-